Literature DB >> 28202664

LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis.

Mattia Volta1, Heather Melrose2.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD), resembling the sporadic disorder. Intensive effort has been directed toward LRRK2 mouse modeling and investigation, aimed at reproducing the human disease to inform mechanistic studies of pathogenesis and design of neuroprotective therapies. The physiological function of LRRK2 is still under exploration, but a clear role in striatal neurophysiology and animal behavior has emerged. Alterations in LRRK2 impair dopamine (DA) transmission, regulation and signaling, in addition to corticostriatal synaptic plasticity. Consistently, several subtle abnormalities in motor and nonmotor abilities have been demonstrated in LRRK2 genetic mouse models, generally paralleling preclinical symptoms of early DA dysfunction. However, the variability in model design and phenotypes observed requires a critical approach in interpreting the results, adapting the model used to the specific research question. Etiologically appropriate knockin mice might represent the ultimate animal model in which to study early disease mechanisms and therapies as well as to investigate drug effectiveness and off-target consequences.
© 2017 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Parkinson's disease; animal behavior; leucine-rich repeat kinase; neurotransmission; striatum

Mesh:

Substances:

Year:  2017        PMID: 28202664     DOI: 10.1042/BST20160238

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  22 in total

1.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

Review 2.  Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.

Authors:  Vinod Udayar; Yu Chen; Ellen Sidransky; Ravi Jagasia
Journal:  Trends Neurosci       Date:  2022-01-13       Impact factor: 13.837

Review 3.  Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.

Authors:  Mattia Volta
Journal:  Neurotherapeutics       Date:  2022-09-09       Impact factor: 6.088

Review 4.  Are we listening to everything the PARK genes are telling us?

Authors:  Deanna L Benson; George W Huntley
Journal:  J Comp Neurol       Date:  2019-02-08       Impact factor: 3.215

Review 5.  New Developments in Genetic rat models of Parkinson's Disease.

Authors:  Rose B Creed; Matthew S Goldberg
Journal:  Mov Disord       Date:  2018-02-08       Impact factor: 10.338

6.  Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.

Authors:  Alessandro Tozzi; Michela Tantucci; Saverio Marchi; Petra Mazzocchetti; Michele Morari; Paolo Pinton; Andrea Mancini; Paolo Calabresi
Journal:  Cell Death Dis       Date:  2018-02-12       Impact factor: 8.469

7.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

Review 8.  Physiological and pathological functions of LRRK2: implications from substrate proteins.

Authors:  Miho Araki; Genta Ito; Taisuke Tomita
Journal:  Neuronal Signal       Date:  2018-10-10

9.  LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.

Authors:  Changyoun Kim; Alexandria Beilina; Nathan Smith; Yan Li; Minhyung Kim; Ravindran Kumaran; Alice Kaganovich; Adamantios Mamais; Anthony Adame; Michiyo Iba; Somin Kwon; Won-Jae Lee; Soo-Jean Shin; Robert A Rissman; Sungyong You; Seung-Jae Lee; Andrew B Singleton; Mark R Cookson; Eliezer Masliah
Journal:  Sci Transl Med       Date:  2020-10-14       Impact factor: 17.956

Review 10.  From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2.

Authors:  Andrea Mancini; Petra Mazzocchetti; Miriam Sciaccaluga; Alfredo Megaro; Laura Bellingacci; Dayne A Beccano-Kelly; Massimiliano Di Filippo; Alessandro Tozzi; Paolo Calabresi
Journal:  Front Cell Neurosci       Date:  2020-07-28       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.